B

Bio-Techne

Purified proteins and reagents supplier

Graduate Data Analyst Intern-Operations & Supply Chain

Summer 2026Updated
$16.80 - $23.10/hr
Internship
Master's
Minneapolis, MN, USA
In Person
Data & AnalyticsData Analysis

About the job

Requirements
  • Currently enrolled in a Master’s degree in Supply Chain, Operations, Business Analytics, Industrial Engineering, Finance, or a related field
  • Strong analytical mindset with demonstrated interest in operations, manufacturing, or supply chain analytics
  • Strong proficiency in Excel and hands-on experience with SQL and/or Power BI
  • Ability to work with complex, imperfect datasets and ask structured, insight driven questions
  • Strong attention to detail with a desire to understand how systems, data, and processes interact
  • Clear and professional communication skills, with the ability to explain analytical findings to diverse audiences
  • Motivation to learn enterprise analytics tools, planning concepts, and operational workflows in a fast-paced environment
Responsibilities
  • Analytics & Reporting Ownership: Design, build, and maintain analytical dashboards and data models using Power BI, SQL, and Excel to support critical supply chain metrics, including inventory health, backlog, on-time delivery (OTD), and production flow. Ensure outputs are accurate, scalable, and decision-ready.
  • Supply Chain Data Analysis: Analyze complex datasets from ERP and MRP systems, demand plans, and operational reports to identify trends, risks, and root causes of performance gaps. Translate findings into clear insights that support planning and execution decisions.
  • Inventory & Planning Insights: Support inventory planning and forecasting efforts by analyzing usage patterns, supply variability, and demand signals. Help surface inventory risks such as shortages, excess, and misalignment between demand, supply, and production constraints.
  • MRP & Master Data Analysis: Develop an understanding of how BOM structures, lead times, lot sizes, and planning parameters impact operational outcomes. Assist in validating data inputs and analyzing MRP signals to improve planning accuracy and execution reliability.
  • Operational Problem Solving: Contribute to high-impact analytics initiatives focused on improving execution performance, reducing decision noise, and increasing clarity for planning, manufacturing, and operations teams. Support structured problem solving using data-driven approaches.
  • Automation & Process Improvement: Assist in streamlining manual reporting and improving data consistency by supporting automation, standardization, and improved data pipelines, helping enable faster and more reliable decision-making.
  • Cross-Functional Collaboration: Work closely with stakeholders across manufacturing, planning, customer service, logistics, and analytics to understand operational workflows and ensure analytics outputs are aligned to real execution needs.
  • Documentation & Knowledge Sharing: Document analytical logic, assumptions, definitions, and learnings to support repeatable, scalable, and well-governed analytics solutions within the supply chain analytics ecosystem.
Desired Qualifications
  • Prior academic, research, or internship experience in supply chain, operations, manufacturing, or analytics
  • Exposure to ERP or MRP systems through coursework, projects, or work experience
  • Familiarity with statistics, forecasting, or basic modeling techniques
  • Experience using Power BI, SQL, Python, or similar tools in academic or practical settings
  • Interest in process improvement, Lean thinking, or operational problem-solving frameworks
  • Ability to independently explore data, validate assumptions, and propose next-step analyses

About the company

B

Bio-Techne

View
Website

Bio-Techne makes and sells life-science tools such as purified proteins, cytokines, growth factors, antibodies, immunoassays, and reagent solutions, along with ProteinSimple analytics and cell/gene therapy workflow technologies. Researchers use these products to produce, analyze, and quantify biomolecules and to carry out assays and workflow steps in cancer, immunology, and regenerative medicine. The company differentiates itself with a broad, integrated catalog and end-to-end support—from raw proteins to analytical solutions—delivered to a global customer base. Its goal is to be a leading provider of life-science tools that speed up discovery and development in healthcare and biology.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Minneapolis, MN

Founded

1981

Get referred to Bio-Techne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Bio-Techne shareholders approved Merck’s acquisition on September 23, 2026, clearing a major hurdle.
  • August 12, 2026 results showed 3% organic fourth-quarter growth and 310-basis-point margin expansion.
  • July 2026 AI-engineered proteins expand cell-therapy demand and strengthen advanced culture workflows.

What critics are saying

  • Merck’s $73-per-share acquisition closes late 2026 or early 2027, ending independence.
  • Fiscal 2026 revenue stayed flat at $1.2 billion, exposing weak organic demand.
  • Restructuring through fiscal 2027 and Merck integration threaten roles, autonomy, and duplicated functions.

What makes Bio-Techne unique

  • Bio-Techne’s 50-year protein catalog still anchors customer loyalty across research workflows.
  • ProteinSimple, RNAscope, and spatial biology create sticky, integrated tools across discovery.
  • The Düsseldorf Customer Experience Center deepens European adoption of Bio-Techne workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Short-term Disability
  • Long-term Disability
  • Pet Insurance
  • Legal Services
  • 401(k) Company Match
  • Company Equity
  • Professional Development Budget
  • Paid Vacation

Growth & Insights and Company News

6 month growth

3%

1 year growth

3%

2 year growth

3%
Watchlist News
Oct 22nd, 2026
Bio-Techne (NASDAQ:TECH) hits new 12-month high - time to Buy?

Bio-Techne (NASDAQ:TECH) hits new 12-month high - time to Buy? Bio-Techne Corp (NASDAQ:TECH - Get Free Report) shares reached a new 52-week high during trading on Thursday. The stock traded as high as $72.69 and last traded at $72.6350, with a volume of 2,591,160 shares traded. The stock had previously closed at $72.64. Analyst ratings changes. A number of analysts recently weighed in on TECH shares. Citigroup lowered shares of Bio-Techne from a "buy" rating to a "neutral" rating and upped their target price for the stock from $70.00 to $73.00 in a research note on Friday, June 26th. Leerink Partners set a $73.00 price objective on shares of Bio-Techne in a research report on Thursday, June 25th. Wells Fargo & Company downgraded Bio-Techne from an "overweight" rating to an "equal weight" rating and increased their price target for the stock from $62.00 to $73.00 in a report on Thursday, August 13th. Royal Bank Of Canada lowered Bio-Techne from an "outperform" rating to a "sector perform" rating and lifted their price objective for the company from $62.00 to $73.00 in a report on Thursday, July 9th. Finally, William Blair cut shares of Bio-Techne from an "outperform" rating to a "market perform" rating in a research note on Thursday, June 25th. Two equities research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. Based on data from MarketBeat, Bio-Techne presently has a consensus rating of "Hold" and a consensus price target of $68.92. Bio-Techne trading down 0.0%. The business's 50 day moving average is $72.41 and its 200-day moving average is $64.31. The firm has a market cap of $11.39 billion, a P/E ratio of 63.15, a price-to-earnings-growth ratio of 8.86 and a beta of 1.30. The company has a quick ratio of 3.35, a current ratio of 4.55 and a debt-to-equity ratio of 0.09. Bio-Techne (NASDAQ:TECH - Get Free Report) last issued its earnings results on Wednesday, August 12th. The biotechnology company reported $0.52 EPS for the quarter, meeting analysts' consensus estimates of $0.52. The company had revenue of $321.19 million during the quarter, compared to the consensus estimate of $314.63 million. Bio-Techne had a return on equity of 13.23% and a net margin of 14.97%. Bio-Techne's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.53 earnings per share. As a group, analysts forecast that Bio-Techne Corp will post 1.72 earnings per share for the current fiscal year. Bio-Techne increases dividend. The business also recently disclosed a quarterly dividend, which was paid on Friday, September 4th. Shareholders of record on Monday, August 24th were issued a dividend of $0.65 per share. This represents a $2.60 annualized dividend and a yield of 3.6%. The ex-dividend date was Monday, August 24th. This is a boost from Bio-Techne's previous quarterly dividend of $0.08. Bio-Techne's dividend payout ratio is presently 27.83%. Institutional trading of Bio-Techne. Several hedge funds and other institutional investors have recently modified their holdings of the company. Root Financial Partners LLC acquired a new stake in shares of Bio-Techne in the third quarter worth about $27,000. Nisa Investment Advisors LLC boosted its holdings in shares of Bio-Techne by 0.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 69,072 shares of the biotechnology company's stock worth $5,006,000 after acquiring an additional 620 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Bio-Techne by 31.7% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 5,408 shares of the biotechnology company's stock worth $392,000 after purchasing an additional 1,302 shares in the last quarter. AdvisorNet Financial Inc boosted its holdings in Bio-Techne by 10.8% in the third quarter. AdvisorNet Financial Inc now owns 3,381 shares of the biotechnology company's stock valued at $245,000 after acquiring an additional 330 shares during the last quarter. Finally, ZWJ Investment Counsel Inc. lifted its stake in shares of Bio-Techne by 4.8% in the 3rd quarter. ZWJ Investment Counsel Inc. now owns 3,971 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 183 shares during the period. 98.95% of the stock is currently owned by hedge funds and other institutional investors. Bio-Techne company profile. Bio-Techne Corporation is a life sciences company that develops and supplies research and diagnostic products for biotechnology, pharmaceutical, academic, clinical and other laboratory customers. The company supports biological research, drug discovery and development, and diagnostic testing through a portfolio of reagents, instruments and analytical technologies. Its products include proteins, antibodies, immunoassays, flow cytometry reagents, molecular biology tools and cell culture materials. Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.

AZoM.com Limited
Oct 8th, 2026
Bio-Techne expands global GMP manufacturing network with new Bristol facility to advance scalable cell therapy development.

Bio-Techne expands global GMP manufacturing network with new Bristol facility to advance scalable cell therapy development. Bio-Techne Corporation, a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market. The investment reflects Bio-Techne's commitment to helping therapy developers address one of the industry's most pressing challenges: establishing scalable, reproducible manufacturing processes that can support programs from early development through commercialization. A guide to advancing biotherapeutic research eBook. Welcome to your essential guide to advancing biotherapeutic research. The purpose-built 10,000-square-foot Bristol facility features five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small molecule manufacturing and product handling. Designed to meet the rigorous standards required for advanced cell therapy manufacturing, the facility enhances Bio-Techne's ability to provide customers with high-quality GMP materials supported by robust quality systems and reliable global supply. "As the cell therapy field continues to mature, success increasingly depends on the ability to manufacture therapies consistently and at scale," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Our investment in Bristol demonstrates Bio-Techne's commitment to providing customers with the GMP materials, manufacturing expertise, and supply chain reliability needed to accelerate development and ultimately bring transformative therapies to patients worldwide." The Bristol expansion is the latest milestone in Bio-Techne's broader strategy to build a comprehensive manufacturing network supporting every stage of the cell therapy workflow. Together with the company's recombinant protein manufacturing operations in Minneapolis, Minnesota, its extensive GMP capabilities in St Paul, and its strategic relationship with Wilson Wolf Corporation, a leading manufacturer of cell culture devices including the widely adopted G-Rex(R) platform, Bio-Techne offers an increasingly integrated portfolio of GMP proteins, GMP small molecules, GMP cell media, custom manufacturing services, analytical solutions, and process development support. Collectively, these capabilities help customers transition seamlessly from research through clinical development and commercial production. Cell therapy developers face mounting pressure to reduce variability, standardize manufacturing processes, and scale production efficiently while meeting evolving regulatory expectations. Bio-Techne addresses these challenges through high-quality GMP materials, scalable manufacturing solutions, and analytical technologies designed to improve consistency and accelerate development timelines. Recent industry discussions have increasingly highlighted manufacturing scalability as a critical factor in enabling broader patient access to advanced therapies, reinforcing the importance of investments such as the Bristol expansion. The opening of its Bristol facility represents more than additional manufacturing capacity. It strengthens Bio-Techne's ability to serve as a long-term partner for cell therapy innovators by providing the quality, scale, and global support necessary to navigate the journey from discovery to commercial supply." Will Geist, President of Bio-Techne's Protein Sciences Segment The Bristol facility is fully operational and is manufacturing GMP-grade small molecules that support customers developing next-generation cell therapies worldwide. Be the first to rate this article

Contract Pharma
Oct 8th, 2026
Bio-Techne opens gmp-grade small-molecule manufacturing facility in Bristol, UK.

Bio-Techne opens gmp-grade small-molecule manufacturing facility in Bristol, UK. The site further expands Bio-Techne's global capabilities in supporting a burgeoning cell therapy market. October 8, 2026 Content Marketing Editor Editor's Take: Combining with Bio-Techne's capabilities in Minnesota, this comes amid a pending acquisition by Merck KGaA, Darmstadt, Germany. Bio-Techne opened a new manufacturing facility in Bristol, United Kingdom, for good manufacturing practice (GMP)-grade small molecules. The site further expands Bio-Techne's global capabilities in terms of supporting the growing cell therapy market. As a provider of life science tools, reagents, and diagnostic products, Bio-Techne helps therapy developers address pressing industry challenges. One of the foremost of these is establishing scalable and reproducible manufacturing processes to support early development through commercialization. GMP conditions crucial. To this end, the purpose-built, 10,000-square-foot Bristol facility has five ISO-8 multifunctional cleanrooms, and two ISO-7 cleanrooms. These areas are dedicated to GMP small molecule manufacturing and product handling, meeting rigorous requirements for advanced cell therapy manufacturing. As such, with this facility Bio-Techne offers customers high-quality GMP materials backed by robust quality systems and reliable global supply. Pending Bio-Techne acquisition by Merck KGaA. The facility's opening comes amid Bio-Techne's pending acquisition by Merck KGaA, Darmstadt, Germany. That $11 billion deal was announced in June 2026. In September, Bio-Techne shareholders approved the transaction. It should be closing in late 2026 or early 2027. Why Bristol? But back to Bristol, Bio-Techne says it reflects a broader strategy to build a comprehensive manufacturing network in cell therapy. It joins recombinant protein manufacturing operations and other GMP capabilities in the company's home state of Minnesota. "Success increasingly depends on the ability to manufacture therapies consistently and at scale," Bio-Techne President and CEO Kim Kelderman said. "Our investment in Bristol demonstrates Bio-Techne's commitment to providing customers with [needed] GMP materials, manufacturing expertise, and supply chain reliability." The Bristol facility is now fully operational, manufacturing GMP-grade small molecules supporting global customers who are developing next-generation cell therapies. Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Yahoo Finance
Sep 24th, 2026
Bio-Techne stock up 37% annually, outpacing Nasdaq's 19% despite flat $1.2B revenue

Bio-Techne Corporation, a Minneapolis-based life science company valued at $11.4 billion, has significantly outperformed the Nasdaq Composite in recent months. The stock gained 28.9% over the past three months, compared to the Nasdaq's 5.3% rise during the same period. Year-to-date, Bio-Techne shares climbed 23.3%, whilst advancing 37% over the past 52 years, surpassing the Nasdaq's YTD gains of 15.9% and annual returns of 19.3%. The company reported mixed financial results, with full-year sales remaining flat at $1.2 billion due to sluggish biotech funding and uneven biopharma demand. However, disciplined cost controls and operational efficiencies improved GAAP operating margins and net earnings. In its Q4 results announced in August, Bio-Techne met earnings expectations with adjusted EPS of $0.52, whilst revenue of $321.2 million exceeded Wall Street forecasts of $317.2 million.

Newswire
Sep 22nd, 2026
Bio-Techne opens new Customer Experience Center in Düsseldorf to accelerate scientific discovery and customer collaboration.

Bio-Techne opens new Customer Experience Center in Düsseldorf to accelerate scientific discovery and customer collaboration. Sep 22, 2026, 09:00 ET * New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise * Regional hub will support researchers and organizations across the DACH and broader EMEA regions * Center strengthens collaboration, training and innovation within Europe's life sciences community MINNEAPOLIS and DÜSSELDORF, Germany, Sept. 22, 2026 /CNW/ - Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise. The new center serves as a regional hub where researchers, biopharmaceutical companies, biotechnology innovators and clinical laboratories can explore integrated technologies and workflows firsthand, helping accelerate scientific discovery, translational research and clinical impact. Located in one of Europe's leading centers for academic research and innovation, the Düsseldorf Customer Experience Center enables customers throughout the Germany, Austria, and Switzerland (DACH) region and the broader Europe, Middle East, and Africa (EMEA) region to engage directly with Bio-Techne scientists, technologies and solutions. The center has been designed to showcase integrated workflows in a single environment, giving researchers the opportunity to evaluate technologies, gain hands-on experience and identify approaches that can advance scientific discovery and improve patient outcomes. Through demonstrations and interactive learning experiences, visitors can explore techniques and applications across protein biology, spatial biology, cell therapy, molecular diagnostics, and analytical instrumentation. Beyond customer engagement, the Düsseldorf center will serve as a regional hub for learning, training, and collaboration. The facility will host workshops, thought leadership events and technical training programs while strengthening Bio-Techne's engagement with universities, research institutes and emerging biotechnology companies throughout the region. Professor Jörg Wischhusen, Ph.D. University Hospital Würzburg, scientific founder CatalYm and co-founder Toleris Biotherapeutics said, "Getting direct access to Bio-Techne's technologies, workflows and scientific experts in one location is an exciting prospect for researchers like us. The ability to evaluate technologies firsthand and experience complete workflows in action should help to make faster and more informed decisions that can accelerate research and development." "Researchers increasingly need partners who can help bridge discovery, translational research and clinical application," said Frank Splettstoesser, Experimental Anesthesiology AG Frede, University Hospital Bonn. "The Düsseldorf Customer Experience Center provides an environment where scientists can learn, collaborate, and explore innovative solutions that address complex biological questions. It demonstrates Bio-Techne's commitment to supporting scientific excellence across Europe." "The opening of our Düsseldorf Customer Experience Center represents a significant investment in the scientific community across Europe," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Our goal is to provide researchers and clinicians with the tools, technologies and expertise they need to answer complex biological questions and improve human health. By creating a destination where scientists can experience innovative techniques firsthand, collaborate with our experts, and evaluate integrated workflows, we are helping accelerate breakthroughs from research to real-world impact." Düsseldorf Mayor Dr. Stephan Keller said, "Bio-Techne's investment in Düsseldorf reflects the strength of our region as a center for life science innovation and international business. We welcome the company's continued expansion and commitment to North Rhine-Westphalia and our city, further reinforcing our strong life sciences ecosystem and collaborative environment that benefits researchers, institutions and businesses alike." The new center also reflects Bio-Techne's commitment to sustainable growth and long-term investment in Europe. Located within a refurbished facility designed with modern energy-efficient features, the site provides convenient access for customers across Germany and the broader region while creating capacity for future expansion as customer needs evolve. By bringing together innovation, expertise and collaboration in a single location, the Düsseldorf Customer Experience Center reinforces Bio-Techne's commitment to empowering scientists with the tools and technologies needed to reach better answers and advance the future of life science research and healthcare. ABOUT BIO-TECHNE Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems(TM), Bio-Techne Spatial(TM), and Bio-Techne Diagnostics(TM), reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. MEDIA CONTACTS Investor Relations David Clair, Vice President [email protected] SOURCE Bio-Techne Corporation

INACTIVE